Connect with Us

Email Sign Up


    Clinical Trials for Netherton Syndrome

    Quoin Pharmaceuticals is developing QRX003, a topical lotion designed to addres s the underlying mechanisms of Netherton Syndrome. Currently, Quoin is conducting four ongoing investigational studies evaluating QRX003’s safety, efficacy, and potential as the first approved treatment for this devastating condition.

    Follow us on: